Business Context and Reporting Period
This Form 8-K Current Report is filed by Synta Pharmaceuticals Corp. (not Madrigal Pharmaceuticals, Inc., as indicated in the metadata request) on April 28, 2008. The filing discloses the execution of severance and change of control agreements with specific executive officers, approved by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements and does not contain financial performance data.
Material Changes
The material change reported is the formalization of severance and change of control terms for Senior Vice Presidents and Vice Presidents. These agreements define compensation triggers for terminations "without Cause" or for "Good Reason," as well as enhanced benefits in the event of a Change of Control.
Management Commentary and Agreements
Management has established the following terms for the named executive officers (excluding the CEO):
- Senior Vice Presidents (Drs. Barsoum, Jacobson, Koya):
- Standard Termination: 6 months of base salary, acceleration of stock options vesting for the 6-month period, and 6 months of health benefits.
- Change of Control Termination: 12 months of base salary, prorated target annual bonus, full acceleration of all outstanding equity awards, and 12 months of health benefits.
- Vice Presidents (Mr. Ehrlich):
- Standard Termination: 3 months of base salary, acceleration of stock options vesting for the 3-month period, and 3 months of health benefits.
- Change of Control Termination: Entitled to the same enhanced payments and benefits as the Senior Vice Presidents (12 months salary, bonus, full equity acceleration, 12 months health benefits).
- Conditions: Receipt of all payments is conditioned on the officer executing a written release of claims against Synta.
Investor Verification Checklist
- Verify the specific definitions of "Cause," "Good Reason," and "Change of Control" in the full text of Exhibits 10.1 and 10.2.
- Confirm the current base salary and target bonus amounts for the named officers to calculate potential liability.
- Review the total number of outstanding stock options held by the named officers to assess the impact of full acceleration.
- Check for any subsequent filings regarding the actual termination of these officers or a Change of Control event.